Facebook
Twitter
LinkedIn
Forward
We are at a unique place in obesity care history where anti-obesity medications (AOMs) are showing promising, clinically significant weight loss for persons with obesity.
|
This presentation will provide an overview of the evidence basis for using continuous glucose monitoring (CGM) in patients with obesity.
|
Weight stigma is an often-overlooked contributor to poor patient engagement and weight gain over time.
|
|
OMA Clinical Practice Statement Updates - Harold Bays, MD, FOMA, Lydia Alexander, MD, FOMA, Karlijn Burridge, PA-C, Suzanne Cuda, MDCME/CE Expiration Date: 3/19/25
|
As the tools continue to advance in Obesity Medicine, it can be easy to overlook the importance of the Behavior pillar in treating obesity.
|
We are amidst a paradigm shift in obesity treatment, spurred by the introduction of newer, highly effective anti-obesity medications.
|
This session will discuss strategies to increase access to obesity care while mitigating provider burnout.
|
This session covers the employer health benefit landscape and how it has changed over the last five years due to COVID, new treatments, technology, and competition.
|
In this session, co-presented by a primary care and an obesity-focused tertiary care provider, we will review barriers and facilitators to pediatric obesity treatment in primary and tertiary care s
|